Boehringer inks $500m Sitryx deal, secures CPNV-driven Hernexeos approval
Boehringer Ingelheim has revamped its portfolio and pipeline by inking a immunology-focused licensing deal with Sitryx Therapeutics worth more than…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
GSK continues dealmaking spree with $950m 35Pharma acquisition
Less than 24 hours after inking a $1bn licensing deal with Frontier BioSciences, GSK has agreed to acquire Canadian biotech…
-
GSK backs siRNA modality through $1bn Frontier deal
GSK has doubled down on its belief in the silent interfering RNA (siRNA) modality by inking a licensing agreement worth up to just over $1bn with Chinese…
-
Gilead acquires CAR-T specialist Arcellx for $7.8bn
Gilead has agreed to acquire Arcellx in a deal worth $7.8bn, as the drugmaker looks to add a CAR T-cell…
-
Novo Nordisk flags board members for re-election amid restructuring efforts
In a bid to regain operational stability, Novo Nordisk’s Board of Directors has nominated two new members to join the committee, which has…
-
Ex-Trump official-ran Altesa secures $75m in Series B funding round
Altesa BioSciences has closed an oversubscribed $75m Series B funding round to advance the clinical development of its antiviral, vapendavir.…
-
J&J to build $1bn US CGT manufacturing site in Pennsylvania
Johnson & Johnson (J&J) has chosen Pennsylvania as home to its new $1bn cell therapy manufacturing facility, as the Trump…
-
FDA to review Moderna’s flu jab on agency pivot
Following its previous refusal to review Moderna’s seasonal flu vaccine, mRNA-1010, the US Food and Drug Administration (FDA) has changed…
-
Pricing and reimbursement delays continue to impact biopharma revenue streams
Delays in obtaining pricing and reimbursement (P&R) have been identified as key hurdles holding back the pharmaceutical industry, according to…
-
PTC pulls Translarna NDA after unfavourable FDA feedback
PTC Therapeutics has chosen to withdraw its resubmitted new drug application (NDA) for Duchenne muscular dystrophy (DMD) therapy, Translarna (ataluren),…